MRNS250117P500
- 0.05
- 0.000.00%
Marinus Pharmaceuticals Newsroom
Truist Financial Maintains Marinus Pharmaceuticals(MRNS.US) With Hold Rating
Baird Maintains Marinus Pharmaceuticals(MRNS.US) With Hold Rating, Cuts Target Price to $0.55
Immedica to Buy Marinus Pharmaceuticals for $151m
Express News | Marinus Pharmaceuticals Inc : Baird Raises Target Price to $0.55 From $0.50
12 Health Care Stocks Moving In Monday's Pre-Market Session
Shareholder Alert: Ademi LLP Investigates Whether Marinus Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday
Sector Update: Health Care
KKR, Impilo's Immedica Pharma Agrees Purchase of Marinus Pharmaceuticals
The Global rare disease company Immedica intends to acquire Marinus Pharmaceuticals (MRNS.US) for Cash.
Global rare disease company Immedica Pharma will acquire Marinus through a tender offer and subsequent merger. As of the time of writing, Marinus's stock price surged 44% in pre-market trading on Monday.
Orion Terminates Drug Distribution Deal With Marinus Pharmaceuticals
Immedica Pharma to Acquire Marinus Pharmaceuticals in Strategic Merger For $0.55/Share Implying An Enterprise Value Of $151M
Express News | Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
Immedica To Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc. MRNS
Express News | Trading Halt: Halted at 6:55:00 A.m. ET - Trading Halt: Halt News Pending
Express News | Marinus Pharmaceuticals Inc - on Dec 6, Receives Nasdaq Notice for Minimum Bid Price Deficiency
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results
Marinus Pharmaceuticals Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
Express News | D. Boral Capital Maintains Buy on Marinus Pharma, Maintains $3 Price Target
JMP Securities Maintains Marinus Pharmaceuticals(MRNS.US) With Hold Rating